Hong Kong stocks fluctuate | Beigene (06160) opened nearly 4%, using the flagship biopharmaceutical production base and clinical research center in the United States.

Beigene (06160) opened nearly 4% higher and rose 3.70% to HKD 96.60 at the time of release with a turnover of HKD 6.5371 million.

Zhitong Finance21:24 ET

BeiGene Ltd. to Announce Mid-Year Financials

TipRanksJul 24 08:38 ET

BEIGENE: DATE OF AUDIT COMMITTEE MEETING

Hong Kong Stock ExchangeJul 24 08:26 ET · Announcements

BeiGene Opens Biologics Facility in New Jersey, US

Yahoo FinanceJul 24 06:33 ET

Express News | Beigene : JP Morgan Raises Target Price to $194 From $186

ReutersJul 24 00:23 ET

Beigene has started using its flagship biopharmaceutical production base and clinical research center in the USA to continue driving global business expansion and bringing innovative drugs to more patients worldwide.

The new flagship facility located in New Jersey, USA, with a total investment of 0.8 billion US dollars, has advanced production capacity and clinical development capabilities for new anti-cancer drugs, which will support the company's global business growth and expansion. Hopewell, New Jersey, USA, July 23, 2024 / PRNewswire / - BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) is a global innovative oncology company. Today, it announced the official opening of its new flagship base in Princeton West Innovation Park, Hopewell, New Jersey, USA. The base has been built with world-class technology.

PR NewswireJul 23 08:26 ET